Securities code: 688221 securities abbreviation: Frontier Biotechnologies Inc(688221) Announcement No.: 2022-002 Frontier Biotechnologies Inc(688221) Pharmaceutical (Nanjing) Co., Ltd
Stock trading abnormal fluctuation announcement
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Frontier Biotechnologies Inc(688221) within three consecutive trading days (January 13, 2022, January 14, 2022 and January 17, 2022) of stock trading of Pharmaceutical (Nanjing) Co., Ltd. (hereinafter referred to as “the company” or “the company”), the cumulative deviation of closing price increase has reached 30%. According to the trading rules of Shanghai Stock Exchange and the special provisions on stock trading on the science and Innovation Board of Shanghai Stock Exchange The relevant provisions of the detailed rules for real-time monitoring of abnormal stock trading on the science and Innovation Board of Shanghai Stock Exchange (for Trial Implementation) belong to abnormal fluctuations in stock trading.
After the company’s self-examination and sent a letter to the actual controller of the company, in addition to the disclosed information, the company and the actual controller have no other major information that should be disclosed but not disclosed, and the information disclosed by the company in the early stage does not need to be corrected or supplemented.
The company’s product under development fb2001 is a new drug under development reported by both China and the United States. As of the disclosure date of this announcement, fb2001 is conducting phase I clinical trials in the United States; In December 2021, fb2001 was approved to carry out phase I bridging clinical trial in China. At present, relevant research is being carried out. The drug research and development of the project in China and the United States are in the early stage of clinical development of new drugs. Affected by multiple factors such as global epidemic development and vaccination, the clinical progress and clinical results are uncertain, and the project will not have a significant impact on the company’s performance in the short term. Please make rational decisions and invest prudently.
The company’s product fb2001 under development is a covid-19 pneumonia virus protease inhibitor for injection, and the target is covid-19 pneumonia virus 3CL main protease. As of the disclosure date of this announcement, Pfizer’s oral covid-19 drug (paxlovid) has been authorized by the U.S. Food and Drug Administration (FDA) for emergency use to treat patients with adverse prognosis risk For non hospitalized patients with mild to moderate covid-19 pneumonia, the company’s product fb2001 is a protease inhibitor for injection, which is intended to treat hospitalized patients with moderate and severe covid-19 pneumonia; As of the disclosure date of this announcement, the drugs approved for the treatment of hospitalized patients with covid-19 pneumonia include remdesivir of Gilead company. New drug research and development is a long-term work, and the sales of new drugs after listing is affected by multiple factors such as global epidemic development, overseas policies, business environment and listing of competitive products. There is still uncertainty whether the follow-up commercial promotion can achieve the expected benefits. Please make rational decisions and invest prudently.
The company’s stock has increased by more than 30% in the last three consecutive trading days, and the continuous rise of stock price has accumulated more profit adjustment risks. The company specially reminds investors that the company’s share price may have the risk of correction. Please pay attention to the investment risk, avoid following the trend of speculation, make rational decisions and invest prudently. 1、 Details of abnormal fluctuations in stock trading
Within three consecutive trading days (January 13, 2022, January 14, 2022 and January 17, 2022), the deviation of the closing price increase has reached 30% in total. According to the trading rules of Shanghai Stock Exchange and the special provisions on stock trading on the science and Innovation Board of Shanghai Stock Exchange The relevant provisions of the detailed rules for real-time monitoring of abnormal stock trading on the science and Innovation Board of Shanghai Stock Exchange (for Trial Implementation) belong to abnormal fluctuations in stock trading. 2、 Relevant information concerned and verified by the company
In view of the abnormal fluctuation of the company’s stock trading, after the company’s self inspection, the relevant information is described as follows:
(I) daily operation
1. Sales of core product aikening
As of September 30, 2021, the company has achieved an operating revenue of about 34.6453 million yuan, mainly from the sales revenue of core product aikening; By the end of the third quarter of 2021, the company has covered more than 170 designated HIV treatment hospitals and more than 80 DTP pharmacies in 27 provinces and municipalities directly under the central government, 108 prefecture level cities and key counties in China.
In October 2021, the Thirteenth National AIDS and hepatitis C academic conference of the Chinese Medical Association issued the China AIDS diagnosis and treatment guideline (2021 Edition), and introduced the new therapy of long acting HIV fusion inhibitor Ike Ning, as a recommended treatment plan for HIV post exposure prevention, to introduce finger south.
2. Research and development progress of products under development
Fb2001, a product under development, is a covid-19 pneumonia virus (sars-cov-2) protease inhibitor for injection. As of the disclosure date of this announcement, fb2001 is conducting phase I clinical trials in the United States; In December 2021, fb2001 was approved to carry out phase I bridging clinical trial in China. At present, relevant research is being carried out.
Fb1002, a product under development, is a combination of long-acting and injectable anti HIV drugs composed of aikonin combined with 3bnc117 antibody. It is planned to be administered every 2-4 weeks. As of the disclosure date of this announcement, the treatment indications have been maintained, and the second phase of phase II clinical trial has been launched in the United States; The international multicenter phase II clinical trial has been launched for the indication of multidrug resistance; The indications of immunotherapy have been launched in phase II clinical trials in China.
Fb3001 is a product under development and a new transdermal analgesic patch is under development. As of the disclosure date of this announcement, fb3001 has completed the phase I clinical trial of bridging in China and is promoting the research and development related work in the next stage.
In case of any subsequent important R & D progress, the company will disclose it in accordance with the regulatory provisions and in combination with the actual situation, and the relevant contents shall be subject to the announcement disclosed by the company.
(II) major events
After the company sent a written letter to Mr. Dong Xie, the actual controller of the company, the company confirmed that as of the disclosure date of this announcement, Mr. Dong Xie, the actual controller of the company, had no major events affecting the abnormal fluctuation of stock trading of the listed company; There are no other major information about the company that should be disclosed but not disclosed, including but not limited to major asset restructuring, issuance of shares, acquisition of listed companies, debt restructuring, business restructuring, asset divestiture and asset injection, and there are no major events in the planning stage; It is not found that the information disclosed in the previous period needs to be corrected and supplemented.
(III) other stock price sensitive information
As of the disclosure date of this announcement, the company has not found any media reports or market rumors that may have a great impact on the company’s stock trading price, and has not found any other major events that may have a great impact on the company’s stock price.
The directors, supervisors, senior managers, actual controllers and persons acting in concert of the company do not buy or sell the company’s shares during the abnormal fluctuation of stock trading.
Nanjing Shenggong venture capital center (limited partnership), the shareholder of the company, issued an announcement on reducing the company’s shares. For details, please refer to the website of Shanghai Stock Exchange (www.sse. Com. CN.) on November 6, 2021 and December 11, 2021 And the information disclosure media designated by the company, the announcement on the share reduction plan of shareholders of Frontier Biotechnologies Inc(688221) Pharmaceutical (Nanjing) Co., Ltd. (Announcement No.: 2021-043) and the suggestive announcement on changes in shareholders’ equity of Frontier Biotechnologies Inc(688221) Pharmaceutical (Nanjing) Co., Ltd. (Announcement No.: 2021-046). As of the disclosure date of this announcement, the implementation of the reduction plan has not been completed.
The shareholder of the company, Shanghai Zhongcheng Hongyun business information consulting service firm (limited partnership), issued the announcement related to the reduction of the company’s shares. For details, see the website of Shanghai Stock Exchange (www.sse. Com. CN.) on December 27, 2021 and January 8, 2022 And the information disclosure media designated by the company, the announcement on the share reduction plan of shareholders of Frontier Biotechnologies Inc(688221) Pharmaceutical (Nanjing) Co., Ltd. (Announcement No.: 2021-048) and the suggestive announcement on changes in shareholders’ equity of Frontier Biotechnologies Inc(688221) Pharmaceutical (Nanjing) Co., Ltd. (Announcement No.: 2022-001). As of the disclosure date of this announcement, the implementation of the reduction plan has not been completed. 3、 Board statement
The board of directors of the company confirms that, except for the matters that have been disclosed in accordance with the provisions, the company has no matters that should be disclosed but not disclosed in accordance with the relevant provisions of the Listing Rules of science and Innovation Board of Shanghai Stock Exchange or the planning and intention related to such matters, and the board of directors has not been informed of the matters that should be disclosed but not disclosed in accordance with the relevant provisions of the Listing Rules of science and Innovation Board of Shanghai Stock Exchange Information that may have a great impact on the trading price of the company’s shares and their derivatives. 4、 Relevant risk tips
The company solemnly requests investors to make rational decisions and invest prudently, and especially reminds investors to pay attention to the following risk factors: 1. The company’s product fb2001 under research is a new drug under research reported by China and the United States. As of the disclosure date of this announcement, fb2001 is carrying out phase I clinical trial in the United States; In December 2021, fb2001 was approved to carry out phase I bridging clinical trial in China. At present, relevant research is being carried out. The drug research and development of the project in China and the United States are in the early stage of clinical development of new drugs. Affected by multiple factors such as global epidemic development and vaccination, the clinical progress and clinical results are uncertain, and the project will not have a significant impact on the company’s performance in the short term. Please make rational decisions and invest prudently.
2. The company’s product fb2001 under development is a covid-19 pneumonia virus protease inhibitor for injection, and the target is covid-19 pneumonia virus 3CL main protease. As of the disclosure date of this announcement, Pfizer’s oral covid-19 drug (paxlovid) has been authorized by the U.S. Food and Drug Administration (FDA) for emergency use to treat patients with adverse prognosis risk For non hospitalized patients with mild to moderate covid-19 pneumonia, the company’s product fb2001 is a protease inhibitor for injection, which is intended to treat hospitalized patients with moderate and severe covid-19 pneumonia; As of the disclosure date of this announcement, the drugs approved for the treatment of hospitalized patients with covid-19 pneumonia include remdesivir of Gilead company. New drug research and development is a long-term work, and the sales of new drugs after listing is affected by multiple factors such as global epidemic development, overseas policies, business environment and listing of competitive products. There is still uncertainty whether the follow-up commercial promotion can achieve the expected benefits. Please make rational decisions and invest prudently.
3. The company’s stock has increased by more than 30% in the last three consecutive trading days, and the continuous rise of stock price has accumulated more profit adjustment risks. The company specially reminds investors that the company’s share price may have the risk of correction. Please pay attention to the investment risk, avoid following the trend of speculation, make rational decisions and invest prudently.
4. The company solemnly reminds investors that China Securities News, Shanghai Securities News, securities daily and securities times are the designated information disclosure newspapers of the company, and the website of Shanghai Stock Exchange (www.sse. Com. CN.) It is the information disclosure website designated by the company. All information of the company shall be subject to the information published in the above designated media. The company will continue to fulfill the obligation of information disclosure in strict accordance with the provisions and requirements of relevant laws and regulations, and do a good job of information disclosure in time. Please invest rationally and pay attention to investment risks.
According to the requirements of the company law, securities law and other relevant laws and regulations, the company will truthfully, accurately, timely, completely and fairly disclose major information that may affect the company’s stock price to investors for investment judgment. Limited by objective conditions, the company is unable to grasp the causes and trends of stock market changes. The company reminds investors to pay attention to stock price fluctuations and possible risks in the stock market in the future.
It is hereby announced.
Frontier Biotechnologies Inc(688221) board of directors of Pharmaceutical (Nanjing) Co., Ltd
January 18, 2022
